Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER Says Keeping Avastin Breast Cancer Claim Would Undermine Accelerated Approval Process

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Center for Drug Evaluation and Research intends to argue at a June hearing that the accelerated approval system will operate as a lower standard if bevacizumab's breast cancer indication is maintained while Genentech conducts another confirmatory trial.
Advertisement

Related Content

Cancer Approval Standards, FDA Reputation At Stake With Avastin Hearing, NEJM Authors Say
Cancer Approval Standards, FDA Reputation At Stake With Avastin Hearing, NEJM Authors Say
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Accelerated Approval Program’s Future Is On The Line At Avastin Hearing
Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval
CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing
Genentech Appeals To FDA's "Regulatory Flexibility"
Genentech Appeals To FDA's "Regulatory Flexibility"
Halaven Survival Data Was Gold-Standard Lining In Forced Shift From Accelerated To Full Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS072240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel